Clinical Pharmacokinetics

, Volume 25, Issue 2, pp 126–135

Pharmacokinetic Optimisation of Inhaled Steroid Therapy in Asthma

  • Ian Pavord
  • Alan Knox
Pharmacokinetic-Therapeutics

DOI: 10.2165/00003088-199325020-00005

Cite this article as:
Pavord, I. & Knox, A. Clin-Pharmacokinet (1993) 25: 126. doi:10.2165/00003088-199325020-00005
  • 13 Downloads

Summary

The recognition that asthma has a large inflammatory component has led to the use of steroids in its treatment. The adverse systemic effects of the drugs have promoted the development of inhaled steroids with a high topical to systemic potency ratio.

The 2 most widely used agents are beclomethasone dipropionate and budesonide. Budesonide has a longer plasma elimination half-life than beclomethasone dipropionate but a higher topical to systemic potency ratio. These agents have been shown to be equipotent with respect to their anti-asthma effects but budesonide may have a slightly more favourable adverse effect profile. At low dosages (up to 400 μg/day) these drugs are well tolerated. At higher dosages (>1000 μg/day) adverse effects on bone metabolism and adrenal function have been noted. Other agents such as triamcinolone or flunisolide have no obvious advantages.

We recommend that inhaled steroids should be prescribed at the lowest dose required to control symptoms, with the dose being increased or decreased in a stepwise manner in parallel with asthma severity.

Copyright information

© Adis International Limited 1993

Authors and Affiliations

  • Ian Pavord
    • 1
  • Alan Knox
    • 1
  1. 1.Division of Respiratory Medicine Unit, Department of MedicineCity HospitalNottinghamEngland